announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® (naloxone HCl) Nasal Spray, an 8 mg ...

The nasal spray, called Neffy ... "For people who are on commercial insurance, the cost is going to be limited to about $25," Gounder said. "And then for people who are underinsured or uninsured ...

The nasal route offers a number of benefits over some of the traditional routes of administration for biologics.

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. "We are thrilled ...

“The availability of epinephrine nasal spray may reduce barriers to rapid ... For people with severe allergic reactions who have commercial insurance that covers Neffy, ARS said it will use ...

The event will detail the commercial strategy for etripamil nasal spray (proposed trade name CARDAMYST™), showcasing the company's focus on innovation in its product offerings for managing ...

ARS Pharmaceuticals chief commercial officer Eric Karas stated ... In 2024, ALK-Abelló acquired the rights to neffy adrenaline nasal spray in Europe and Canada, amongst other regions, from ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance ... its robust commercial and medical ...

Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your medical conditions, especially if you have ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...